Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

NGEN stock hub

NervGen Pharma Corp. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NGENis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

303.5M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

NGEN

In the news

Latest news · NGEN

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-1,457.6

P25 -105.6P50 -46.5P75 -3.1

ROIC-508.3

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NGEN market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

164

Groups with data

Currency

CAD

Showing 164 of 164 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001751912
Company name	NervGen Pharma Corp.
Country	Canada
Country code	US
Cusip	64082X203
Employees	7
Enterprise value	$287.4M
Exchange	NASDAQ
Financial currency	CAD
First seen	2026-05-09
Industry	Biotechnology
Isin	CA64082X2032
Last refreshed	2026-05-10
Market cap	$303.5M
Market cap category	Small-Cap
Price	$3.75
Price currency	USD
Sector	Healthcare
Symbol	NGEN
Website	https://nervgen.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-10.6%
FCF yield	-4.7%
P/B ratio	117.79x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-32.2M
Net Income Growth Years	0%
Profit Per Employee	$-4.6M
ROA	-73.42
Roa5y	-72.71
ROCE	-721.3
ROE	-1,457.6
Roe5y	-2,128.7
ROIC	-508.3

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	44.97%
Cagr3y	47.03%
Cagr5y	25.6%
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$16.9M
Cash	$16.1M
Current Assets	$16.7M
Current Liabilities	$14.4M
Debt	$6,104
Debt Equity	$0
Equity	$2.5M
Liabilities	$14.4M
Long Term Assets	$248,907
Long Term Liabilities	$-42,847
Net Cash	$16.1M
Net Cash By Market Cap	$5.3
Net Cash Growth	28.55%
Net Debt Equity	$-6.35
Tangible Book Value	$2.2M
Tangible Book Value Per Share	$0.03
WACC	9.08

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.16
Net Working Capital	$-13.9M
Quick ratio	1.12
Working Capital	$2.2M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-7.44%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	44.93%
200-day SMA	3.58
3Y total return	217.93%
50-day SMA	3.96
50-day SMA vs 200-day SMA	50over200
5Y total return	212.5%
All Time High	6.3
All Time High Change	-40.48%
All Time High Date	2026-01-08
All Time Low	0.55
All Time Low Change	581.57%
All Time Low Date	2020-03-25
ATR	0.23
Beta	0.88
Beta1y	0.78
Beta2y	0.45
Ch YTD	-33.04
High	3.93
High52	6.3
High52 Date	2026-01-08
High52ch	-40.48%
Low	3.74
Low52	1.5
Low52 Date	2025-06-02
Low52ch	150%
Ma50ch	-5.33%
Price vs 200-day SMA	4.75%
RSI	44.39
RSI Monthly	57.11
RSI Weekly	48.15
Sharpe ratio	0.82x
Sortino ratio	1.38
Total Return	-7.44%
Tr YTD	-33.04
Tr1m	-5.54%
Tr1w	-0.79%
Tr3m	-3.35%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	1
Analyst Ratings	Strong Buy
Operating Income	$-18.3M
Price target	$18
Price Target Change	$380

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	68,907,924%
Float Percent	85.14%
Net Borrowing	-73,827.6
Shares Insiders	2.5%
Shares Institutions	4.13%
Shares Out	80,930,871
Shares Qo Q	0.47%
Shares Yo Y	7.44%
Short Float	1.85%
Short Ratio	5.82
Short Shares	1.58

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-18.2M
Average Volume	165,708.65x
Bv Per Share	0.03
Ch1m	-5.54
Ch1w	-0.79
Ch1y	44.9
Ch3m	-3.35
Ch3y	217.8
Ch5y	212.5
Ch6m	52.44
Change	-2.6%
Change From Open	-1.06
Close	3.85
Days Gap	-1.56
Depreciation Amortization	40,814.2
Dollar Volume	463,822.5
Earnings Date	2026-05-22
EBIT	$-18.3M
EBITDA	$-18.3M
EPS	$-0.44
F Score	2
FCF	$-14.3M
FCF EV Yield	-4.96x
FCF Per Share	$-0.18
Financing CF	17,331,770
Fiscal Year End	December
Founded	2,017
Investing CF	73,608
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-04-02
Last Report Date	2025-12-31
Last Split Type	Never
Ma150	3.95
Ma150ch	-5.06%
Ma20	3.92
Ma20ch	-4.24%
Net CF	3,502,353
Next Earnings Date	2026-05-22
Open	3.79
Optionable	Yes
Position In Range	5.41
Post Close	3.75
Postmarket Change Percent	6.16
Postmarket Price	$3.98
Price Date	2026-05-08
Ptbv Ratio	135.6
Relative Volume	0.75x
Share Based Comp	3,934,677
Tr6m	52.44%
Volume	123,686

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does NGEN pay a dividend?

Capital-return profile for this ticker.

Performance

NGEN stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NGEN?

Insider, institutional, and short-interest positioning.

Institutional ownership

+4.1%

Float: +85.1% of shares outstanding

Insider ownership

+2.5%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

NGEN momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

44.4

Neutral momentum band

Price vs 200-day MA

+4.7%

50/200-day relationship not available

Beta (5Y)

0.88

Moves roughly with the market

Sharpe ratio

0.82

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NGEN

Hub-level FAQ points readers to the deeper analysis pages.

What is the current NGEN stock rating?

NervGen Pharma Corp. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full NGEN analysis?

The full report lives at /stocks/NGEN/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for NGEN?

The latest report frames NGEN around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the NGEN page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.